Gynecologic oncology最新文献

{"title":"LGBTQIA+ populations still neglected in trials and their health needs","authors":"Gianluca Azzellino , Lia Ginaldi , Massimo De Martinis","doi":"10.1016/j.ygyno.2024.10.002","DOIUrl":"10.1016/j.ygyno.2024.10.002","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"191 ","pages":"Pages 114-115"},"PeriodicalIF":4.5,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer","authors":"Weimin Kong ,&nbsp;Boer Deng ,&nbsp;Xiaochang Shen ,&nbsp;Catherine John ,&nbsp;Jennifer Haag ,&nbsp;Nikita Sinha ,&nbsp;Douglas Lee ,&nbsp;Wenchuan Sun ,&nbsp;Shuning Chen ,&nbsp;Haomeng Zhang ,&nbsp;Angela Clontz ,&nbsp;Stephen D. Hursting ,&nbsp;Chunxiao Zhou ,&nbsp;Victoria Bae-Jump","doi":"10.1016/j.ygyno.2024.10.004","DOIUrl":"10.1016/j.ygyno.2024.10.004","url":null,"abstract":"<div><h3>Objective</h3><div>Interventions that combat obesity and its associated metabolic perturbations may decrease incidence and improve outcomes of endometrial cancer (EC). Potential options for weight loss include pharmacotherapeutic interventions such as tirzepatide, a dual-acting glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist. Given this, we explored the anti-obesity and anti-tumorigenic effects of tirzepatide in our pre-clinical mouse model of endometrioid EC.</div></div><div><h3>Methods</h3><div>Starting at 4 weeks of age, <em>Lkb1</em>^{<em>fl/fl</em>}<em>p53</em>^{<em>fl/fl</em>} mice were fed a low-fat diet vs a high-fat diet to generate a lean or obese phenotype. Nine weeks after induction of EC, obese and lean mice were randomized to receive tirzepatide for 4 weeks. Body and tumor weights, tumor transcriptomic and metabolomic profiles, and serum metabolic markers and chemokines were assessed.</div></div><div><h3>Results</h3><div>Both obese and lean mice began to lose body weight after 2 weeks of tirzepatide treatment, ultimately achieving a significant weight loss of 20.1 % in obese mice and 16.8 % in lean mice. Tirzepatide improved obesity-induced serum adiponectin, leptin, GIP, and C-reactive protein levels. Furthermore, tirzepatide relative to vehicle, effectively reduced tumor growth in obese and lean mice, inhibited the ErbB signaling and glycolysis/gluconeogenesis in tumors of obese mice, and increased O-linked glycosylation biosynthesis and phospholipase D signaling in tumors of lean mice.</div></div><div><h3>Conclusion</h3><div>Tirzepatide decreased both mouse weight and tumor growth via effects on metabolic and immune pathways in the EC tumors that differed between obese and lean mice. This novel weight loss treatment deserves further evaluation as an innovative strategy in the management of EC.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"191 ","pages":"Pages 116-123"},"PeriodicalIF":4.5,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index – A prospective multicentric study using imaging (ISAAC study)","authors":"Patrícia Pinto ,&nbsp;Francesca Moro ,&nbsp;Juan Luis Alcázar ,&nbsp;Sarah Alessi ,&nbsp;Giacomo Avesani ,&nbsp;Klára Benesova ,&nbsp;Andrea Burgetova ,&nbsp;Giuseppina Calareso ,&nbsp;Valentina Chiappa ,&nbsp;David Cibula ,&nbsp;Anna Fagotti ,&nbsp;Dorella Franchi ,&nbsp;Filip Frühauf ,&nbsp;Jiri Jarkovsky ,&nbsp;Roman Kocian ,&nbsp;Lukas Lambert ,&nbsp;Martin Masek ,&nbsp;Camilla Panico ,&nbsp;Paola Pricolo ,&nbsp;Giovanni Scambia ,&nbsp;Daniela Fischerová","doi":"10.1016/j.ygyno.2024.10.003","DOIUrl":"10.1016/j.ygyno.2024.10.003","url":null,"abstract":"<div><h3>Background</h3><div>The aim was to evaluate the performance of the Peritoneal Cancer Index (PCI) using imaging (ultrasound, contrast-enhanced computed tomography (CT), and whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) in assessing peritoneal carcinomatosis and predicting non-resectability in tubo-ovarian carcinoma patients.</div></div><div><h3>Methods</h3><div>This was a prospective multicenter observational study. We considered all patients with suspected primary ovarian/tubal/peritoneal cancer who underwent preoperative ultrasound, CT, and WB-DWI/MRI (if available). The optimal cut off value for assessing the performance of the methods in predicting non-resectability was identified at the point at which the sensitivity and specificity were most similar. The reference standard to predict non-resectability was surgical outcome in terms of residual disease &gt;1 cm or surgery not feasible. Agreement between imaging methods and surgical exploration in assessing sites included in the PCI score was evaluated using the Intraclass Correlation Coefficient (ICC).</div></div><div><h3>Results</h3><div>242 patients were included from January 2020 until November 2022. The optimal PCI cut-off for predicting non-resectability for surgical exploration was &gt;12, which achieved the best AUC of 0.87, followed by ultrasound with a cut-off of &gt;10 and AUC of 0.81, WB-DWI/MRI with a cut-off of &gt;12 and AUC of 0.81, and CT with a cut-off of &gt;11 and AUC of 0.74. Using ICC, ultrasound had very high agreement (0.94) with surgical PCI, while CT and WB-DWI/MRI had high agreement (0.86 and 0.87, respectively).</div></div><div><h3>Conclusion</h3><div>Ultrasound performed by an expert operator had the best agreement with surgical findings compared to WB-DWI/MRI and CT in assessing radiological PCI. In predicting non-resectability, ultrasound was non-inferior to CT, while its non-inferiority to WB-DWI/MRI was not demonstrated.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"191 ","pages":"Pages 132-142"},"PeriodicalIF":4.5,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer","authors":"Nicoletta Colombo ,&nbsp;Toon Van Gorp ,&nbsp;Ursula Matulonis ,&nbsp;Ana Oaknin ,&nbsp;Rachel Grisham ,&nbsp;Diane Provencher ,&nbsp;Gini Fleming ,&nbsp;Alexander Olawaiye ,&nbsp;Hristina Pashova ,&nbsp;Iulia Cristina Tudor ,&nbsp;Lyndah Dreiling ,&nbsp;Domenica Lorusso","doi":"10.1016/j.ygyno.2024.07.109","DOIUrl":"10.1016/j.ygyno.2024.07.109","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"190 ","pages":"Page S74"},"PeriodicalIF":4.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142420826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in National Institute of Health funding for cancer survivorship: A spotlight on breast and gynecologic cancers","authors":"Payden White ,&nbsp;Tanner Barbour ,&nbsp;Alicia Lozano ,&nbsp;Joanna Choi-Klier ,&nbsp;Alexandra Hanlon ,&nbsp;Shannon Armbruster","doi":"10.1016/j.ygyno.2024.07.057","DOIUrl":"10.1016/j.ygyno.2024.07.057","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"190 ","pages":"Pages S35-S36"},"PeriodicalIF":4.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142416732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finding a needle in the haystack: Identifying risk of MDS/AML after PARP inhibitor treatment","authors":"Amma Asare,&nbsp;Sara Corvigno,&nbsp;Nicole Fleming,&nbsp;Shannon Westin,&nbsp;Sanghoon Lee,&nbsp;Koichi Takahashi,&nbsp;Anil Sood","doi":"10.1016/j.ygyno.2024.07.070","DOIUrl":"10.1016/j.ygyno.2024.07.070","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"190 ","pages":"Pages S44-S45"},"PeriodicalIF":4.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142416425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BEATcc (ENGOT-CX10/GEICO 68-C/JGOG-1084/GOG-3030): A randomized phase III trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage IVB), persistent, or recurrent cervical cancer","authors":"Ana Oaknin ,&nbsp;Laurence Gladieff ,&nbsp;Jerónimo Martínez-García ,&nbsp;Guillermo Villacampa ,&nbsp;Munetaka Takekuma ,&nbsp;Ugo De Giorgi ,&nbsp;Kristina Lindemann ,&nbsp;Linn Woelber ,&nbsp;Nicoletta Colombo ,&nbsp;Linda Duska ,&nbsp;Alexandra Leary ,&nbsp;Ana Godoy Ortiz ,&nbsp;Shin Nishio ,&nbsp;Maria Jesús Rubio-Pérez ,&nbsp;Satoshi Yamaguchi ,&nbsp;Domenica Lorusso ,&nbsp;Leslie Randall","doi":"10.1016/j.ygyno.2024.07.037","DOIUrl":"10.1016/j.ygyno.2024.07.037","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"190 ","pages":"Pages S21-S22"},"PeriodicalIF":4.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of survivors teaching students®: A patient-centered experiential educational model of ovarian cancer for rising healthcare professionals","authors":"Susan Leighton,&nbsp;Gwen Harding-Peets,&nbsp;Sarah DeFeo","doi":"10.1016/j.ygyno.2024.07.041","DOIUrl":"10.1016/j.ygyno.2024.07.041","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"190 ","pages":"Page S24"},"PeriodicalIF":4.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful implementation of a goals-to-discharge patient checklist following surgery for gynecologic cancer","authors":"Maureen Byrne,&nbsp;Kara Long Roche,&nbsp;Dennis Chi,&nbsp;Yukio Sonoda,&nbsp;Nadeem Abu-Rustum,&nbsp;Ginger Gardner,&nbsp;Vance Broach","doi":"10.1016/j.ygyno.2024.07.042","DOIUrl":"10.1016/j.ygyno.2024.07.042","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"190 ","pages":"Pages S24-S25"},"PeriodicalIF":4.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study","authors":"Christian Marth ,&nbsp;Richard Moore ,&nbsp;Mariusz Bidzinski ,&nbsp;Sandro Pignata ,&nbsp;Ali Ayhan ,&nbsp;M. Jesús Rubio ,&nbsp;Mario Beiner ,&nbsp;Marcia Hall ,&nbsp;Christof Vulsteke ,&nbsp;Elena Ioana Braicu ,&nbsp;Kenzo Sonoda ,&nbsp;Xiaohua Wu ,&nbsp;Sophia Frentzas ,&nbsp;André Mattar ,&nbsp;Jodi McKenzie ,&nbsp;Lili Yao ,&nbsp;Vivek Khemka ,&nbsp;Robert Orlowski ,&nbsp;Lucy Gilbert ,&nbsp;Vicky Makker","doi":"10.1016/j.ygyno.2024.07.094","DOIUrl":"10.1016/j.ygyno.2024.07.094","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"190 ","pages":"Pages S63-S64"},"PeriodicalIF":4.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142416060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}